AstraZeneca uses genomics and proteomics software
31 January 2007Tweet
AstraZeneca is using Cambridge Cell Network’s (CCnet) genomics and proteomics software ToxWiz to predict the effects of drugs used to treat liver disease.
The user-friendly approach provides a quick way to determine the relationships between side effects and specific proteins or pathways. The software allows researchers to search computational models of more than 500 biological pathways. Each pathway can then connect to a database of 800,000 abstracts.
Dr Scott Bayer, principal scientist and head of computational toxicology at AstraZeneca, said: ‘CCnet is listening in earnest to toxicologists, providing solutions to challenges we face and making appropriate software modifications as they are requested.’